Fresita Proteins Rights Issue 2026: ₹89.76 Crore Plan

Fresita Proteins Ltd has finalised the terms of its proposed rights issue, setting out a fundraise of approximately ₹89.76 crore through the issue of 74,79,917 equity shares. The company’s board approved the terms at its meeting on October 26, 2026. Eligible shareholders will be offered five rights equity shares for every six fully paid equity shares held on the record date. The issue price has been fixed at ₹120 per equity share, against a face value of ₹10 per share. The record date is October 30, 2026. The rights issue is scheduled to open on November 12, 2026 and close on November 26, 2026. The shares are listed on the BSE under scrip code 519242.

Board Approves Final Issue Terms

The board meeting outcome dated October 26 stated that Fresita Proteins had approved and fixed the terms of the rights issue. The approval followed an earlier intimation on October 21 regarding a meeting of the Rights Issue Committee. At that stage, the committee was expected to determine the issue price, entitlement ratio, record date and other terms for a proposed issue of up to ₹90 crore. The final terms place the issue size at approximately ₹89.76 crore. The company will issue 74,79,917 equity shares at ₹120 each. The stated amount is marginally different from the earlier ceiling because the final size is based on the fixed number of shares and issue price. The rights issue is being undertaken through an offering of fully paid equity shares.

Key Dates for Eligible Shareholders

Shareholders must hold Fresita Proteins shares by the applicable settlement deadline to be eligible based on the October 30 record date. The published last date to buy shares is October 29, 2026. The shares are marked ex-rights on October 30, 2026. Rights entitlements can be renounced until November 20, 2026, according to the announced schedule. The issue will open on November 12 and close on November 26. The deemed date of allotment is listed as November 27, 2026. Investors should rely on the company’s formal issue documents and notices for procedural requirements and any updates.

What the 5:6 Ratio Means

The entitlement ratio is 5:6. This means an eligible shareholder will receive the right to apply for five rights shares for every six fully paid equity shares held on the record date. Rights shares are offered at the announced price of ₹120 per share. The ratio does not itself require shareholders to apply for the entire entitlement. A shareholder may apply, renounce rights entitlements where permitted, or take the steps allowed under the offer terms. The final allotment process remains subject to the terms of the issue and applicable regulations. Shareholders should check the rights entitlement credited to their demat account and read the Letter of Offer before acting.

How Investors Can Apply

The published information identifies two online application routes for the issue. Eligible investors may use the Applications Supported by Blocked Amount, or ASBA, facility through net banking if their bank provides it. They may also use the registrar’s web-based application platform, described as the R-WAP facility. Under ASBA, the application amount is blocked in the investor’s bank account in accordance with the process. The material also refers to a Composite Application Form for offline applications. Such forms are generally sent by the registrar and transfer agent to entitled shareholders. Investors using any route should ensure that account and PAN details meet the requirements stated in the issue documents.

Earlier Approval and Company Background

Fresita Proteins was formerly known as Sarda Proteins Limited. On August 5, 2026, the company announced board approval to issue equity shares on a rights basis, with an amount not exceeding ₹10,000 lakh. That amount represents a broad approval limit of up to ₹100 crore. The board also approved a Draft Letter of Offer and constituted a Rights Issue Committee to oversee the process. The October 26 decision converted the earlier proposal into a defined issue with a price, ratio, record date and schedule. The final announced size of about ₹89.76 crore remains within the earlier approved ceiling.

Reconciling the Published Date Information

Some material associated with the issue contains inconsistent references to a subscription period from August 5 to October 30. Those dates do not align with the board-approved schedule stating that the rights issue opens on November 12 and closes on November 26. The October 26 board outcome and the detailed issue schedule both identify November 12 as the opening date. Investors should therefore treat the formal board outcome, stock exchange filings and Letter of Offer as the primary sources for the timeline. The record date remains October 30, 2026 in the published information. Any later exchange announcement or corrigendum would supersede prior operational information.

Capital Structure and Market Relevance

A rights issue allows a listed company to offer new shares first to its existing shareholders in proportion to their holdings. For Fresita Proteins, the issue could raise approximately ₹89.76 crore if fully subscribed. The offer will increase the number of outstanding shares after allotment because 74,79,917 new equity shares are proposed. Existing investors who do not participate may see their proportional ownership change following the issuance. The 5:6 ratio is a large entitlement relative to the existing holding base, making the issue terms relevant for ownership calculations. The reported data does not specify the intended use of proceeds. As a result, no conclusion can be drawn from the available information about deployment of funds or the financial effect on operations.

Regulatory Process and Shareholder Decisions

The company stated that the rights issue process is being conducted under the Companies Act, 2013 and applicable Securities and Exchange Board of India regulations. Rights issues require disclosures through the offer document and stock exchange communication channels. Shareholders should review the issue price, entitlement, application period and renunciation deadline before making a decision. They should also consider the issue documentation rather than relying solely on market summaries. A rights entitlement is distinct from an allotted share and follows its own application and trading or renunciation process where available. The offer’s final allotment and listing-related actions will follow the announced schedule and applicable procedures.

What Comes Next

The immediate date for shareholders is the October 30 record date, with October 29 listed as the last date to buy shares for eligibility. The rights issue will then open on November 12 and remain open until November 26. Rights entitlements may be renounced until November 20, based on the announced timetable. Fresita Proteins has set the issue price at ₹120 and the entitlement at five shares for every six shares held. The company’s October 26 board approval provides the final disclosed commercial terms for the proposed ₹89.76 crore fundraise. Investors should monitor BSE filings and the Letter of Offer for any further notices before the subscription window begins.